Vertex Pharmaceuticals IncorporatedVRTX

Where VRTX's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$546.12-11.84 (-2.12%)Previous close
NASDAQHealthcare

VRTX Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
VRTX Net Debt / EBITDA historyVRTX Net Debt / EBITDA from Sep 2023 to Jun 2026: low -7.84, high 39.65, latest -0.77.-11.642.1315.9129.6843.45Sep 23Mar 24Sep 24Jun 25Dec 25Jun 26med -1.69

VRTX Net Debt / EBITDA by year

Yearly range of VRTX’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from -44.2 to 39.7, averaging -3.2.

VRTX Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
2026-0.8-0.7-0.7-0.8
2025-0.89.539.7-0.2
2024-7.8-5.5-1.7-5.8
2023-2.3-2.1-1.9-2.1
2022-2.2-2.1-1.9-2.2
2021-2.0-1.9-1.6-2.0
2020-1.8-1.6-1.5-1.5
2019-3.1-2.6-1.6-1.6
2018-23.3-8.8-2.4-2.9
2017-44.2-14.4-1.3-10.3
2016-4.8-4.5-4.2-4.8

Get notified when VRTX Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.